The collaboration will focus on ensuring that patients who are eligible for CAR T-cell therapy can access Kite’s treatments when and where they need them.
This transaction represents a meaningful milestone as McKesson executes its separation strategy of MMS in preparation of a planned initial public offering.
Britt Vitalone announces retirement, Kenny Cheung named as successor.
The transaction represents the final step in McKesson’s commitment to fully exit its European operations.
Project affirms commitment to supporting the domestic pharmaceutical industry and strengthens pharmacy supply chain.
Bresnahan pointed out that community pharmacy needs to diversify,“ to respond to the market shifts, [particularly] as traditional prescription volume starts to shift away from traditional retail pharmacy.”
McKesson invites independent pharmacy owners and their teams to register and attend premier education and networking event.
Announces fourth quarter and full year fiscal 2025 earnings release date.
